Mirimus
Business Services · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
760 Parkside Ave Ste 206, Brooklyn, New ...Phone Number
(929) 377-3744Website
www.mirimus.comRevenue
$18.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About Mirimus
Mirimus is an award-winning biotech and preclinical contract research organization (CRO) that specializes in accelerating drug discovery through innovative gene editing and RNAi technologies. They provide high-quality animal and cell models for preclinical testing, enabling researchers to gain precise control over gene expression. Their services include preclinical drug discovery, RNAi services, and the development of 2D/3D in vitro models. Mirimus aims to partner with researchers and organizations focused on advancing human health and developing new therapies for challenging diseases.Explore more
Mirimus Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mirimus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Mirimus recently announced quarterly report
Click to see if Mirimus had a recent Job posting/layoffs
Check out if Mirimus is spiking on competitors!
Funding: Get notified immidiatlly once Mirimus has new funding data
Congratulate Masked Content for being promoted to Masked Content at Mirimus
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Mirimus launches new products
Mirimus, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Mirimus has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Mirimus as Masked Content
Find 3 more new buyers
Compare Similar Companies to Mirimus
Compare insights from companies similar to Mirimus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Mirimus is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Mirimus is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Mirimus.
Mirimus financials insights
Gather financial insights about Mirimus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
Mirimus Tech Stack
A closer look at the technologies used by Mirimus
Most Recent Scoops
Funding
Project
Spending/Investment, Funding
Funding
Project
Award, Spending/Investment
Project
A mid-level source in operations management has indicated that the organization is in the midst of initiatives related to workforce management. Mirimus is currently evaluating vendors to support these efforts. The organization has expressed interest in Rippling and Square solutions.
Workforce Management
Project
A mid-level source in operations management has indicated that the organization is in the midst of initiatives related to capacity planning. Mirimus is currently evaluating vendors to support these efforts. The organization is interested in BioBAT solutions.
Capacity Planning
Project
Facilities Relocation/Expansion
Mirimus News & Media
Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications
NEW YORK, July 21, 2021 /PRNewswire/ -- Mirimus, Inc., a pioneer in RNAi therapeutic design and CRISPR/Cas9 gene editing technology implementation, today announced a strategic collaboration with Biogen Inc. (NASDAQ: BIIB) focused on the development of RNAi-based therapeutics targeting...Mirimus, Inc. Announces Publication of Research in The Lancet-Affiliated Journal EClinicalMedicine Discussing Pooled, Saliva-Based COVID-19 Testing as Efficient, Affordable Surveillance Approach for K-12 Schools
NEW YORK, July 19, 2021 /PRNewswire/ -- Mirimus, Inc., a leader in conducting high-volume, high-quality PCR testing, today announced the publication of a peer-reviewed paper by EClinicalMedicine, an open access medical journal published by The Lancet. The paper, titled, "Implementation of...Meenta Announces Partnership with Mirimus for K-12 Pooled Saliva COVID-19 Testing
BOSTON, May 11, 2021 /PRNewswire/ -- Meenta, a leading provider of COVID-19 testing software for K-12 schools, colleges and universities, is announcing a partnership with Mirimus to bring an unparalleled experience to COVID-19 testing to safely reopen schools. This announcement follows...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mirimus
Sign Up For FreeTo access detailed company insights
Mirimus is an award-winning biotech and preclinical contract research organization (CRO) that specializes in accelerating drug discovery through innovative gene editing and RNAi technologies. They provide high-quality animal and cell models for preclinical testing, enabling researchers to gain precise control over gene expression. Their services in... Read More
